Relapsing Forms of Multiple Sclerosis: Clinical Trials

11 completed, 1 not yet recruiting, 1 suspended, 1 withdrawn. 4 Phase 3, 3 Phase 2, 2 Phase 4, 1 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 3	4	Completed 2, Not yet recruiting 1, Withdrawn 1
Phase 2	3	Completed 2, Suspended 1
Phase 4	2	Completed 2
Early Phase 1	1	Completed 1

Follow Relapsing Forms of Multiple Sclerosis: new trials by email Literature Review of Relapsing Forms of Multiple Sclerosis trials Research Report on Relapsing Forms of Multiple Sclerosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis	Phase 3	Not yet recruiting	Biogen	185	2026-11-16	2026-03-19
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice ofatumumab - Relapsing Forms of Multiple Sclerosis		Completed	Novartis Pharmaceuticals	310	2024-02-26	2025-12-29
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) BIIB091, DRF, Placebo - Relapsing Forms of Multiple Sclerosis	Phase 2	Completed	Biogen	127	2023-07-25	2026-02-20
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel fumarate - Relapsing Forms of Multiple Sclerosis	Phase 3	Completed	Biogen	136	2021-11-18	2025-10-24
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD - Relapsing Forms of Multiple Sclerosis	Phase 2	Suspended	Emerald Health Pharmaceuticals	50	2021-10-19	2022-10-21
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis Ocrelizumab, Ofatumumab - Relapsing Forms of Multiple Sclerosis		Completed	Novartis Pharmaceuticals	2	2021-05-11	2022-10-24
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) dimethyl fumarate, Placebo - Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis	Phase 3	Withdrawn	Biogen		2016-05-01	2016-04-13
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine - Relapsing Forms of Multiple Sclerosis	Phase 2	Completed	Biogen	71	2015-02-28	2017-06-02
Plegridy Observational Program peginterferon beta-1a - Relapsing Forms of Multiple Sclerosis		Completed	Biogen	1208	2014-11-12	2022-09-26
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS dimethyl fumarate - Relapsing Forms of Multiple Sclerosis		Completed	Biogen	333	2013-08-01	2016-07-25
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States BG00012 (DMF) - Relapsing Forms of Multiple Sclerosis	Phase 4	Completed	Biogen	237	2013-05-01	2017-03-21
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis Fingolimod - Relapsing Forms of Multiple Sclerosis	Phase 3	Completed	Novartis Pharmaceuticals	4125	2010-09-13	2021-04-21
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Fingolimod, Standard MS DMTs - Relapsing Forms of Multiple Sclerosis	Phase 4	Completed	Novartis Pharmaceuticals	1053	2010-08-01	2014-02-10
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS) Plasma exchange, natalizumab treatment - Relapsing Forms of Multiple Sclerosis	Early Phase 1	Completed	Biogen	12	2007-01-01	2009-09-04

Narrower conditions

Multiple Sclerosis (6)  ·  Multiple Sclerosis, Relapsing-Remitting (2)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Nervous System Diseases (1)  ·  Recurrence (1)

Broader conditions

Autoimmune Diseases (6)  ·  Demyelinating Autoimmune Diseases, CNS (6)  ·  Demyelinating Diseases (6)  ·  Immune System Diseases (6)  ·  Autoimmune Diseases of the Nervous System (5)  ·  Nervous System Diseases (5)  ·  Disease Attributes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Dimethyl Fumarate (5)  ·  Fingolimod Hydrochloride (3)  ·  diroximel fumarate (2)  ·  ofatumumab (2)  ·  23-valent pneumococcal capsular polysaccharide vaccine (1)  ·  BID protein, human (1)  ·  BIIB091 (1)  ·  Diphtheria-Tetanus Vaccine (1)  ·  Glatiramer Acetate (1)  ·  Interferon beta-1a (1)  ·  Interferon beta-1b (1)  ·  Meningococcal Vaccines (1)  ·  Plasma Exchange (1)  ·  ocrelizumab (1)  ·  peginterferon beta-1a (1)

Sponsors

Biogen (9)  ·  Novartis Pharmaceuticals (4)  ·  Emerald Health Pharmaceuticals (1)

Countries

United States (10)  ·  Australia (4)  ·  Spain (4)  ·  Canada (3)  ·  Germany (3)  ·  Italy (3)  ·  Switzerland (3)  ·  Austria (2)  ·  Czechia (2)  ·  Denmark (2)  ·  France (2)  ·  Ireland (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Portugal (2)

Top investigators

Michael Panzara, MD MPH (1)

Results publications

PMID 23647445, PMID 25424122, PMID 26265273, PMID 26265274, PMID 29159204, PMID 30470580, PMID 31598139, PMID 33225410

NIH funding

2014 (1), 2023 (1)